Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Routinely available
SMC (1291/18)
16/05/2018
Indication
As monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available in line with national guidance
Formulation
25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion
Comments
May 2018 - Routinely available in line with national guidance. Included on the Additional List, for Specialist Use only.